The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience
- 作者: Kolyadina I.1, Bulavina I.2, Petkau V.2, Strakhova N.2, Gorbunova V.1, Kovalenko E.1, Manziuk L.1, Artamonova E.1, Zhukova L.3, Bolotina L.4, Gan'shina I.1, Semiglazova T.5, Manikhas A.6, Raevskaia N.6, Itkin I.6, Khokhlova S.7, Filonenko D.8, Gol'dberg V.9, Popova N.9, Ponomarenko D.10, Shikina V.11, Vladimirova L.12, Tikhanovskaia N.12, Karabina E.13, Mukhametshina G.14, Khasanova A.14, Safina S.14, Shaidorov M.15, Orlov A.16, Kostalanova I.16, Levchenko N.17, Osipov M.18, Karandeeva T.19, Evstigneeva I.20, Chernov I.21, Kolokolov D.22, Povyshev A.23, Shatokhina A.24, Cherniakova E.25, Shkodenko O.26, Kuz'mina E.27
-
隶属关系:
- N.N. Blokhin National Medical Research Center of Oncology
- Sverdlovsk Regional Oncology Center
- A.S. Loginov Moscow Clinical Scientific Practical Center
- P.A. Herzen Moscow Research Institute of Oncology - branch of the National Medical Research Radiological Center
- N.N. Petrov National Medical Research Center of Oncology
- City Clinical Oncology Dispensary
- V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
- Moscow City Oncology Hospital №62
- Research Institute of Oncology of the Tomsk National Research Medical Center
- Regional Oncology Dispensary
- Moscow Regional Oncological Dispensary
- Rostov Research Institute of Oncology
- Tula Regional Oncologic Dispensary
- Republican Clinical Oncology Dispensary
- Tolyatti City Clinical Hospital №5
- Samara Regional Clinical Oncology Dispensary
- Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)
- Leningrad Regional Oncological Dispensary
- D.D. Pletnev City Clinical Hospital
- Tver Regional Clinical Oncology Dispensary
- Oncologic Dispensary №5
- City Polyclinic №195
- District Clinical Hospital
- Clinical Oncology Center №1
- Republican Oncology Center
- Stavropol Regional Clinical Oncology Dispensary
- Salekhard District Clinical Hospital
- 期: 卷 21, 编号 2 (2019)
- 页面: 17-24
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/33500
- DOI: https://doi.org/10.26442/18151434.2019.2.190395
- ID: 33500
如何引用文章
全文:
详细
作者简介
Irina Kolyadina
N.N. Blokhin National Medical Research Center of Oncology
Email: irinakolyadina@yandex.ru
D. Sci. (Med.), Prof.
Irina Bulavina
Sverdlovsk Regional Oncology CenterBranch manager
Vladislav Petkau
Sverdlovsk Regional Oncology CenterHead of the Center
Natalia Strakhova
Sverdlovsk Regional Oncology CenterBranch manager
Vera Gorbunova
N.N. Blokhin National Medical Research Center of OncologyD. Sci. (Med.), Full Prof.
Elena Kovalenko
N.N. Blokhin National Medical Research Center of OncologyCand. Sci. (Med.)
Liudmila Manziuk
N.N. Blokhin National Medical Research Center of OncologyD. Sci. (Med.), Full Prof.
Elena Artamonova
N.N. Blokhin National Medical Research Center of OncologyD. Sci. (Med.)
Liudmila Zhukova
A.S. Loginov Moscow Clinical Scientific Practical CenterD. Sci. (Med.), Prof. of RAS
Larisa Bolotina
P.A. Herzen Moscow Research Institute of Oncology - branch of the National Medical Research Radiological CenterD. Sci. (Med.)
Inna Gan'shina
N.N. Blokhin National Medical Research Center of OncologyCand. Sci. (Med.)
Tatiana Semiglazova
N.N. Petrov National Medical Research Center of OncologyD. Sci. (Med.), Full Prof.
Aleksei Manikhas
City Clinical Oncology DispensaryD. Sci. (Med.)
Natalia Raevskaia
City Clinical Oncology DispensaryBranch manager
Ilia Itkin
City Clinical Oncology DispensaryCand. Sci. (Med.)
Svetlana Khokhlova
V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and PerinatologyD. Sci. (Med.)
Dmitrii Filonenko
Moscow City Oncology Hospital №62Cand. Sci. (Med.)
Viktor Gol'dberg
Research Institute of Oncology of the Tomsk National Research Medical CenterD. Sci. (Med.), Full Prof.
Natalia Popova
Research Institute of Oncology of the Tomsk National Research Medical CenterCand. Sci. (Med.)
Dmitrii Ponomarenko
Regional Oncology DispensaryCand. Sci. (Med.)
Valentina Shikina
Moscow Regional Oncological DispensaryBranch manager
Liubov Vladimirova
Rostov Research Institute of OncologyD. Sci. (Med.), Full Prof.
Natalia Tikhanovskaia
Rostov Research Institute of Oncologychemotherapist
Elena Karabina
Tula Regional Oncologic DispensaryBranch manager
Guzel Mukhametshina
Republican Clinical Oncology DispensaryCand. Sci. (Med.)
Alfiia Khasanova
Republican Clinical Oncology DispensaryCand. Sci. (Med.)
Sufiia Safina
Republican Clinical Oncology DispensaryCand. Sci. (Med.)
Mikhail Shaidorov
Tolyatti City Clinical Hospital №5Cand. Sci. (Med.)
Andrei Orlov
Samara Regional Clinical Oncology DispensaryD. Sci. (Med.)
Iuliia Kostalanova
Samara Regional Clinical Oncology DispensaryCand. Sci. (Med.)
Natalia Levchenko
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)Cand. Sci. (Med.)
Mikhail Osipov
Leningrad Regional Oncological DispensaryCand. Sci. (Med.)
Tatiana Karandeeva
D.D. Pletnev City Clinical Hospitaloncologist
Irina Evstigneeva
Tver Regional Clinical Oncology DispensaryBranch manager
Igor Chernov
Oncologic Dispensary №5Cand. Sci. (Med.)
Dzheims Kolokolov
City Polyclinic №195oncologist
Anton Povyshev
District Clinical Hospitalchemotherapist
Alina Shatokhina
Clinical Oncology Center №1Branch manager
Elena Cherniakova
Republican Oncology CenterBranch manager
Oksana Shkodenko
Stavropol Regional Clinical Oncology DispensaryBranch manager
Evgeniia Kuz'mina
Salekhard District Clinical Hospitaloncologist
参考
- GLOBOCAN 2018; IACR, WHO, 2018; http://gco.iarc.fr/today
- Колядина И.В., Поддубная И.В. Роль капецитабина и эрибулина в лечении метастатического HER2-негативного распространенного рака молочной железы. Современная Онкология. 2018; 20 (3): 26-9. doi: 10.26442/1815-1434_2018.3.26-29
- Колядина И.В., Поддубная И.В. Современные возможности терапии HER2-положительного рака молочной железы (по материалам клинических исследований). Современная Онкология. 2014; 16 (4): 10-20.
- Колядина И.В., Андреева Ю.Ю., Франк Г.А., Поддубная И.В. Роль биологической гетерогенности при рецидивирующем и метастатическом раке молочной железы. Архив патологии. 2018; 80 (6): 62-7.
- San-Gang Wu, Hui Li, Li-Ying Tang et al. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis. https://doi.org/10.1177/1010428317705082.
- Rostami R, Mittal S, Rostami P et al. Brain metastasis in breast cancer: A comprehensive literature review. J Neurooncol 2016; 127: 407-14.
- Lin N.U. Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience 2013; 7: 307.
- Arslan U.Y, Oksuzoglu B, Aksoy S et al. Breast cancer subtypes and outcomes of central nervous system metastases. Breast 2011; 20: 562-7.
- Altundag K, Bondy M.L, Mirza N.Q et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007; 110: 2640-7.
- Arvold N.D, Oh K.S, Niemierko A et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat 2012; 136: 153-60. doi: 10.1007/s10549-012-2243-x
- Pestalozzi B.C, Zahrieh D, Price K.N et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17: 935-44.
- Rades D, Lohynska R, Veninga T et al. Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. Cancer 2007; 110: 2587-92.
- Oehrlich N.E, Spineli L.M, Papendorf F, Park-Simon T-W. Clinical outcome of brain metastases differs significantly among breast cancer subtypes. Oncology Letters 2017; 14: 194-200.
- Li R, Zhang K, Siegal G.P, Shi Wei. Clinicopathological factors associated with survival in patients with breast cancer brain metastasis. Hum Pathol 2017; 64: 53-60.
- Priedigkeit N, Hartmaier R.J, Chen Y, Vareslija D. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases JAMA Oncol 2017; 3 (5): 666-71. doi: 10.1001/jamaoncol.2016.5630
- Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management Authors: N.U. Lin, L.E. Gaspar, FASTRO, FACR, MBA, R. Soffietti.
- Bachelot T, Romieu G, Campone M. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14 (1): 64-71. doi: 10.1016/S1470-2045 (12)70432-1
- Hurvitz S, Singh R, Adams B. Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). Ther Adv Med Oncol 2018; 10: 1758835918807339. doi: 10.1177/1758835918807339
- Fabi A, Alesini D, Valle E et al. T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. Breast 2018; 41: 137-43. doi: 10.1016/j.breast.2018.07.004
- Petrelli F, Ghidini M, Lonati V et al. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis. Eur J Cancer 2017; 84: 141-8. doi: 10.1016/j.ejca.2017.07.024
- Jacot W, Pons E, Frenel J.S et al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res Treat 2016; 157 (2): 307-18. doi: 10.1007/s10549-016-3828-6
- Uncu D, Bayoglu I.V, Arslan UY Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study. Asian Pac J Cancer Prev 2015; 16 (9): 4127-31.
- Linot B, Campone M, Augereau P et al. Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study. J Neurooncol 2014; 117 (2): 253-9. doi: 10.1007/s11060-014-1378-5
- Erten C, Demir L, Somali I et al. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac J Cancer Prev 2013; 14 (6): 3711-7.
- Addeo R, Sperlongano P, Montella L et al. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother Pharmacol 2012; 70 (4): 603-9.
- Sutherland S, Ashley S, Miles D et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. Br J Cancer 2010; 102 (6): 995-1002. doi: 10.1038/sj.bjc.6605586
- Cortes J, O’Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377: 914-23.
- Chang A.Y, Ying X.X. Brain metastases from breast cancer and response to treatment with eribulin: a case series. Breast Cancer (Auck. l) 2015; 9: 19-24. J Clin Oncol 2015.
- Rivera E, Meyers C, Groves M et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 107: 1348-54.
- Ekenel M, Hormigo A.M, Peak S et al. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007; 85: 223-7.
- Rosner D, Nemoto T, Lane W.W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58: 832-9.
- Caraglia M, Addeo R, Costanzo R et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 2006; 57: 34-9.
- Linot B, Campone M, Augereau P et al. Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study. J Neurooncol 2014; 117: 253-9.
- Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85: 1599-605.
- Cocconi G, Lottici R, Bisagni G et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990; 8: 327-34.
- Christodoulou C, Bafaloukos D, Linardou H et al; Hellenic Cooperative Oncology Group. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005; 71: 61-5.
- Болотина Л.В., Манзюк Л.В., Горбунова В.А. и др. Результаты первого ретроспективного анализа данных по применению эрибулина у пациентов с метастатическим раком молочной железы в условиях реальной клинической практики в России. Современная Онкология. 2016; 18 (3): 27-32.
- Манзюк Л.В., Коваленко Е.И., Горбунова В.А. и др. Эффективность и безопасность эрибулина при различных подтипах рака молочной железы: данные из реальной клинической практики в России. Злокачественные опухоли. 2017; 7 (3): 46-56.
- Горбунова В.A., Koлядина И.В., Koваленко E.И. и др. Эффективность и безопасность эрибулина при HER2-отрицательном метастатическом раке молочной железы: данные многолетнего опыта из реальной клинической практики в России. Современная Онкология. 2019; 21 (1): 12-23.